JP2024534639A5 - - Google Patents

Info

Publication number
JP2024534639A5
JP2024534639A5 JP2024518996A JP2024518996A JP2024534639A5 JP 2024534639 A5 JP2024534639 A5 JP 2024534639A5 JP 2024518996 A JP2024518996 A JP 2024518996A JP 2024518996 A JP2024518996 A JP 2024518996A JP 2024534639 A5 JP2024534639 A5 JP 2024534639A5
Authority
JP
Japan
Prior art keywords
seq
tada
hbv
sequence
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024518996A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024534639A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/077105 external-priority patent/WO2023049935A1/en
Publication of JP2024534639A publication Critical patent/JP2024534639A/ja
Publication of JP2024534639A5 publication Critical patent/JP2024534639A5/ja
Pending legal-status Critical Current

Links

JP2024518996A 2021-09-27 2022-09-27 B型肝炎ウイルス感染症を治療するための組成物及び方法 Pending JP2024534639A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163248938P 2021-09-27 2021-09-27
US63/248,938 2021-09-27
US202263357623P 2022-06-30 2022-06-30
US63/357,623 2022-06-30
US202263371634P 2022-08-16 2022-08-16
US63/371,634 2022-08-16
PCT/US2022/077105 WO2023049935A1 (en) 2021-09-27 2022-09-27 Compositions and methods for treating hepatitis b virus infection

Publications (2)

Publication Number Publication Date
JP2024534639A JP2024534639A (ja) 2024-09-20
JP2024534639A5 true JP2024534639A5 (https=) 2025-10-06

Family

ID=85721334

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024518996A Pending JP2024534639A (ja) 2021-09-27 2022-09-27 B型肝炎ウイルス感染症を治療するための組成物及び方法

Country Status (8)

Country Link
US (1) US20240294914A1 (https=)
EP (1) EP4408986A4 (https=)
JP (1) JP2024534639A (https=)
KR (1) KR20240111821A (https=)
CN (1) CN119013394A (https=)
AU (1) AU2022353130A1 (https=)
CA (1) CA3233413A1 (https=)
WO (1) WO2023049935A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025126049A2 (en) * 2023-12-11 2025-06-19 Crispr Therapeutics Ag Multiplex gene editing

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2966170A1 (en) * 2014-07-10 2016-01-13 Heinrich-Pette-Institut Leibniz-Institut für experimentelle Virologie-Stiftung bürgerlichen Rechts - HBV inactivation
CA3001351A1 (en) * 2015-10-21 2017-04-27 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating hepatitis b virus
KR101842131B1 (ko) * 2016-09-05 2018-03-27 연세대학교 산학협력단 Hbv를 표적으로 하는 유전자 가위 및 이를 포함하는 hbv 감염 치료용 조성물
US11566236B2 (en) * 2018-02-05 2023-01-31 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of hemoglobinopathies
CA3139324A1 (en) * 2019-05-10 2020-11-19 Beam Therapeutics Inc. Compositions and methods for treating hepatitis b

Similar Documents

Publication Publication Date Title
CN113631708B (zh) 编辑rna的方法和组合物
JP7698828B2 (ja) Rnaを編集する方法および組成物
JP2025170240A5 (https=)
JP2024138268A5 (https=)
JP2022546608A5 (https=)
JP2024038326A5 (https=)
US20180236103A1 (en) Crispr/cas-related methods and compositions for treating hepatitis b virus
JP2025102768A5 (https=)
JP2021523736A5 (https=)
JP2024038327A5 (https=)
JP2022519882A5 (https=)
EP2966170A1 (en) HBV inactivation
JP2022532139A5 (https=)
US11499151B2 (en) Methods and systems for analyzing guide RNA molecules
JP2024520528A5 (https=)
JP2022533673A5 (https=)
JP2024501246A5 (https=)
Zhou et al. Efficient silencing of hepatitis B virus S gene through CRISPR‐mediated base editing
JP2024506375A5 (https=)
JP2024534639A5 (https=)
US20250288691A1 (en) Compositions and methods for epigenetic regulation of hbv gene expression
US5856085A (en) Compositions and methods of developing oligonucleotides and oligonucleotide analogs having antiviral activity
US20240294914A1 (en) Compositions and methods for treating hepatitis b virus infection
CA3147641A1 (en) Compositions and methods for modulating apolipoprotein b (apob) gene expression
Sommer et al. A new class of defective hepatitis B virus genomes with an internal poly (dA) sequence